The UK government plans to ban vaping in public places, citing health concerns about exposure to nicotine and toxicants. However, this decision is not backed by scientific evidence supporting vaping as a safer alternative to smoking. Previous reviews by Public Health England found no significant health risks from passive vaping. The proposed ban lacks justification and could deter smokers from switching to less harmful alternatives. Banning vaping without conclusive evidence of harm may infringe on personal freedoms and perpetuate misconceptions about the risks of vaping compared to smoking. A precautionary approach without substantial risk assessment could hinder tobacco harm reduction efforts.

A survey by Ifop reveals that many French smokers buy cigarettes from abroad due to high taxes and regulations. Over half sourced products internationally, with wealthier consumers often traveling for cheaper options. Illicit markets are also prevalent, particularly among young, low-income individuals. The study found illegal vapes still in use despite bans. Cost primarily influences consumer choices, with many willing to turn to non-traditional channels if prices rise. Despite concerns, safety risks do not deter buyers. The research, based on 3,000 respondents, highlights the complex nature of France's tobacco and vaping market behavior.

The United States’ decision to leave the World Health Organization is seen as a major turning point for policy in the Asia-Pacific region, according to the Coalition of Asia Pacific Tobacco Harm Reduction Advocates (CAPHRA). The group is urging governments to review the WHO Framework Convention on Tobacco Control (FCTC), while New Zealand’s Foreign Minister Winston Peters has also questioned continued funding for the treaty. The US cited WHO mismanagement as a reason for its withdrawal, and Peters criticized the organization as unaccountable and in need of taxpayer scrutiny. CAPHRA’s Executive Coordinator, Nancy Loucas, argued that the US exit should prompt a reassessment of the FCTC, particularly regarding its approach to harm reduction tools such as vaping and nicotine pouches.

In this instalment of the “Harm Reduction Heroes” series, Snusforumet speaks with Mark Tyndall, a Canadian infectious-disease physician who played a key role in developing pragmatic responses to HIV and overdose crises. He now argues that the global refusal to embrace safer nicotine alternatives represents a major public health failure that remains largely overlooked despite its clear consequences.

The European Commission fails to uphold its promise of evidence-based legislation with the Tobacco Products Directive update. Misinformation and ignoring harm reduction success stories in Member States like Sweden, the Czech Republic, and Greece are concerning. Public input is dismissed, with citizens supporting harm reduction strategies being ignored in favor of anti-nicotine organizations. Accusations of fake consultation responses fuel a smear campaign. The Commission risks harming public health by equating nicotine products with cigarettes. Embracing harm reduction is crucial for saving lives. The Commission must prioritize facts, listen to science, and respect democratic voices in policymaking for a smoke-free future.